Table 1.
Clinical characteristics in propensity score-matched group
| Variable | Total (N = 378) | Use of regdanvimab (N = 189) | No use of regdanvimab (N = 189) | p value |
|---|---|---|---|---|
| Male | 221 (58.5%) | 112 (59.3%) | 109 (57.7%) | 0.754 |
| Age | 0.918 | |||
| < 50 | 156 (41.3%) | 79 (41.8%) | 77 (40.7%) | |
| 50–59 | 65 (17.2%) | 34 (18.0%) | 31 (16.4%) | |
| 60–69 | 77 (20.4%) | 35 (18.5%) | 42 (22.2%) | |
| 70–79 | 52 (13.8%) | 26 (13.8%) | 26 (13.8%) | |
| ≥ 80 | 28 (7.4%) | 15 (7.9%) | 13 (6.9%) | |
| Body mass index ≥ 30 kg/m2 | 46 (12.2%) | 29 (15.3%) | 17 (9.0%) | 0.059 |
| Medical comorbidities | ||||
| Myocardial infarction | 11 (2.9%) | 6 (3.2%) | 5 (2.6%) | 0.760 |
| Heart failure | 7 (1.9%) | 2 (1.1%) | 5 (2.6%) | 0.449 |
| Cardiovascular disease | 3 (0.8%) | 3 (1.6%) | 0 (0.0%) | 0.248 |
| Neurovascular disease | 21 (5.6%) | 11 (5.8%) | 10 (5.3%) | 0.822 |
| Chronic obstructive pulmonary disease | 3 (0.8%) | 3 (1.6%) | 0 (0.0%) | 0.248 |
| Connective tissue disease | 11 (2.9%) | 7 (3.7%) | 4 (2.1%) | 0.359 |
| Chronic liver disease | 14 (3.7%) | 10 (5.3%) | 4 (2.1%) | 0.102 |
| Diabetes | 67 (17.7%) | 42 (22.2%) | 25 (13.2%) | 0.022 |
| Chronic kidney disease | 11 (2.9%) | 5 (2.6%) | 6 (3.2%) | 0.760 |
| Solid tumor | 0.458 | |||
| Localized | 34 (9.0%) | 16 (8.5%) | 18 (9.5%) | |
| Metastatic | 5 (1.3%) | 4 (2.1%) | 1 (0.5%) | |
| Vaccination status | ||||
| None | 225 (59.5%) | 112 (59.3%) | 113 (59.8%) | 0.917 |
| One dose | 46 (12.2%) | 23 (12.2%) | 23 (12.2%) | 1 |
| Two-dose | 104 (27.5%) | 51 (27.0%) | 53 (28.0%) | 0.818 |
| Three-dose | 3 (0.8%) | 3 (1.6%) | 0 (0.0%) | 0.248 |
| Severity on admission | 0.506 | |||
| Mild | 309 (81.7%) | 152 (80.4%) | 157 (83.1%) | |
| Moderate | 69 (18.3%) | 37 (19.6%) | 32 (16.9%) | |
| Fever (temperature ≥ 37.5 °C) | 178 (47.1%) | 95 (50.3%) | 83 (43.9%) | 0.216 |
| Symptoms | ||||
| Dyspnea | 58 (15.3%) | 28 (14.8%) | 30 (15.9%) | 0.775 |
| Cough | 179 (47.4%) | 92 (48.7%) | 87 (46.0%) | 0.607 |
| Diarrhea | 13 (3.4%) | 6 (3.2%) | 7 (3.7%) | 1 |
| Sputum | 75 (19.8%) | 33 (17.5%) | 42 (22.2%) | 0.246 |
| Sore throat | 97 (25.7%) | 41 (21.7%) | 56 (29.6%) | 0.077 |
| Fatigue | 7 (1.9%) | 4 (2.1%) | 3 (1.6%) | 1 |
| Myalgia | 80 (21.2%) | 39 (20.6%) | 41 (21.7%) | 0.801 |
| Nausea | 1 (0.3%) | 0 (0.0%) | 1 (0.5%) | 1 |
| Pneumonia at admission | 72 (19.0%) | 37 (19.6%) | 35 (18.5%) | 0.793 |